🚀 VC round data is live in beta, check it out!
Camp4 Therapeutics Valuation Multiples
Discover revenue and EBITDA valuation multiples for Camp4 Therapeutics and similar public comparables like Arcturus Therapeutics, Medeze Group, Voyager Therapeutics, Adimmune and more.
Camp4 Therapeutics Overview
About Camp4 Therapeutics
Camp4 Therapeutics Corp is a clinical stage biopharmaceutical company pioneering the discovery and development of regulatory RNA-based therapeutics to upregulate gene expression and restore healthy protein levels to treat various genetic diseases. It focuses on genetic diseases of the central nervous system and liver. The group's pipeline products are CMP-CPS-001 and CMP-SYNGAP.
Founded
2015
HQ
Employees
55
Website
Sectors
Financials (LTM)
EV
$164M
Camp4 Therapeutics Financials
Camp4 Therapeutics reported last 12-month revenue of $4M and negative EBITDA of ($76M).
In the same LTM period, Camp4 Therapeutics generated ($76M) in EBITDA losses and had net loss of ($74M).
Revenue (LTM)
Camp4 Therapeutics P&L
In the most recent fiscal year, Camp4 Therapeutics reported revenue of $3M and EBITDA of ($50M).
Camp4 Therapeutics expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $4M | XXX | $3M | XXX | XXX | XXX |
| EBITDA | ($76M) | XXX | ($50M) | XXX | XXX | XXX |
| EBITDA Margin | (2090%) | XXX | (1442%) | XXX | XXX | XXX |
| EBIT Margin | (1673%) | XXX | (1488%) | XXX | XXX | XXX |
| Net Profit | ($74M) | XXX | ($80M) | XXX | XXX | XXX |
| Net Margin | (2029%) | XXX | (2299%) | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Camp4 Therapeutics Stock Performance
Camp4 Therapeutics has current market cap of $233M, and enterprise value of $164M.
Market Cap Evolution
Camp4 Therapeutics' stock price is $4.49.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $164M | $233M | 0.0% | XXX | XXX | XXX | $-1.55 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialCamp4 Therapeutics Valuation Multiples
Camp4 Therapeutics trades at 44.9x EV/Revenue multiple, and (2.1x) EV/EBITDA.
EV / Revenue (LTM)
Camp4 Therapeutics Financial Valuation Multiples
As of March 23, 2026, Camp4 Therapeutics has market cap of $233M and EV of $164M.
Equity research analysts estimate Camp4 Therapeutics' 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Camp4 Therapeutics has a P/E ratio of (3.1x).
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $233M | XXX | $233M | XXX | XXX | XXX |
| EV (current) | $164M | XXX | $164M | XXX | XXX | XXX |
| EV/Revenue | 44.9x | XXX | 46.9x | XXX | XXX | XXX |
| EV/EBITDA | (2.1x) | XXX | (3.3x) | XXX | XXX | XXX |
| EV/EBIT | (2.7x) | XXX | (3.2x) | XXX | XXX | XXX |
| P/E | (3.1x) | XXX | (2.9x) | XXX | XXX | XXX |
| EV/FCF | (4.6x) | XXX | (5.5x) | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Camp4 Therapeutics Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Camp4 Therapeutics Margins & Growth Rates
Camp4 Therapeutics' revenue in the last 12 month grew by 22%.
Camp4 Therapeutics' revenue per employee in the last FY averaged $0.1M.
Camp4 Therapeutics' rule of 40 is (2068%) (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Camp4 Therapeutics' rule of X is (2035%) (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
Camp4 Therapeutics Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 22% | XXX | 20% | XXX | XXX | XXX |
| EBITDA Margin | (2090%) | XXX | (1442%) | XXX | XXX | XXX |
| EBITDA Growth | (23%) | XXX | 12% | XXX | XXX | XXX |
| Rule of 40 | — | XXX | (2068%) | XXX | XXX | XXX |
| Bessemer Rule of X | — | XXX | (2035%) | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.1M | XXX | XXX | XXX |
| G&A Expenses to Revenue | 491% | XXX | 496% | XXX | XXX | XXX |
| R&D Expenses to Revenue | 1065% | XXX | 1092% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 1588% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Camp4 Therapeutics Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Arcturus Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Medeze Group | XXX | XXX | XXX | XXX | XXX | XXX |
| Voyager Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Adimmune | XXX | XXX | XXX | XXX | XXX | XXX |
| Alector | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Camp4 Therapeutics M&A Activity
Camp4 Therapeutics acquired XXX companies to date.
Last acquisition by Camp4 Therapeutics was on XXXXXXXX, XXXXX. Camp4 Therapeutics acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Camp4 Therapeutics
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialCamp4 Therapeutics Investment Activity
Camp4 Therapeutics invested in XXX companies to date.
Camp4 Therapeutics made its latest investment on XXXXXXXX, XXXXX. Camp4 Therapeutics invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Camp4 Therapeutics
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Camp4 Therapeutics
| When was Camp4 Therapeutics founded? | Camp4 Therapeutics was founded in 2015. |
| Where is Camp4 Therapeutics headquartered? | Camp4 Therapeutics is headquartered in United States. |
| How many employees does Camp4 Therapeutics have? | As of today, Camp4 Therapeutics has over 55 employees. |
| Who is the CEO of Camp4 Therapeutics? | Camp4 Therapeutics' CEO is Joshua Mandel-Brehm. |
| Is Camp4 Therapeutics publicly listed? | Yes, Camp4 Therapeutics is a public company listed on Nasdaq. |
| What is the stock symbol of Camp4 Therapeutics? | Camp4 Therapeutics trades under CAMP ticker. |
| When did Camp4 Therapeutics go public? | Camp4 Therapeutics went public in 2024. |
| Who are competitors of Camp4 Therapeutics? | Camp4 Therapeutics main competitors are Arcturus Therapeutics, Medeze Group, Voyager Therapeutics, Adimmune. |
| What is the current market cap of Camp4 Therapeutics? | Camp4 Therapeutics' current market cap is $233M. |
| What is the current revenue of Camp4 Therapeutics? | Camp4 Therapeutics' last 12 months revenue is $4M. |
| What is the current revenue growth of Camp4 Therapeutics? | Camp4 Therapeutics revenue growth (NTM/LTM) is 22%. |
| What is the current EV/Revenue multiple of Camp4 Therapeutics? | Current revenue multiple of Camp4 Therapeutics is 44.9x. |
| Is Camp4 Therapeutics profitable? | No, Camp4 Therapeutics is not profitable. |
| What is the current EBITDA of Camp4 Therapeutics? | Camp4 Therapeutics has negative EBITDA and is not profitable. |
| What is Camp4 Therapeutics' EBITDA margin? | Camp4 Therapeutics' last 12 months EBITDA margin is (2090%). |
| What is the current EV/EBITDA multiple of Camp4 Therapeutics? | Current EBITDA multiple of Camp4 Therapeutics is (2.1x). |
| What is the current FCF of Camp4 Therapeutics? | Camp4 Therapeutics' last 12 months FCF is ($36M). |
| What is Camp4 Therapeutics' FCF margin? | Camp4 Therapeutics' last 12 months FCF margin is (975%). |
| What is the current EV/FCF multiple of Camp4 Therapeutics? | Current FCF multiple of Camp4 Therapeutics is (4.6x). |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.